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Human embryonic stem cells (hESCs) are able to proliferate in vitro indefinitely without losing their ability to differentiate into
multiple cell types upon exposure to appropriate signals. Particularly, the ability of hESCs to differentiate into neuronal subtypes
is fundamental to develop cell-based therapies for several neurodegenerative disorders, such as Alzheimer’s disease, Huntington’s
disease, and Parkinson’s disease. In this study, we differentiated hESCs to dopaminergic neurons via an intermediate stage, neural
progenitor cells (NPCs). hESCs were induced to neural progenitor cells by Dorsomorphin, a small molecule that inhibits BMP
signalling. The resulting neural progenitor cells exhibited neural bipolarity with high expression of neural progenitor genes and
possessed multipotential differentiation ability. CBF1 and bFGF responsiveness of these hES-NP cells suggested their similarity
to embryonic neural progenitor cells. A substantial number of dopaminergic neurons were derived from hES-NP cells upon
supplementation of FGF8 and SHH, key dopaminergic neuron inducers. Importantly, multiple markers of midbrain neurons were
detected, including NURR1, PITX3, and EN1, suggesting that hESC-derived dopaminergic neurons attained the midbrain identity.
Altogether, thiswork underscored the generation of neural progenitor cells that retain the properties of embryonic neural progenitor
cells.These cells will serve as an unlimited source for the derivation of dopaminergic neurons, whichmight be applicable for treating
patients with Parkinson’s disease.
1. Introduction
Human embryonic stem cells (hESCs) have the ability to
renew and differentiate into multiple cell types of the three
germ layers upon exposure to appropriate signals [1]. Con-
siderably, the differentiation of hESCs in culture appears to
follow the hierarchical set of signals that regulate embryonic
development in the generation of the germ layers and specific
cell types [2]. Besides, hESCs provide a valid model to under-
stand the complex signaling interactions during early embry-
onic development. Parkinson’s disease (PD) is an incurable
and progressive condition characterized by the continuing
degeneration of dopaminergic (DA) neurons in the midbrain
substantia nigra. The specific loss of DA neurons makes
cell-based replacement a promising strategy to cure PD
patients. Previous clinical studies involving transplantation of
embryonic ventral mesencephalic tissues in PD patients have
proved the feasibility of cell-based therapy in this disease;
however, this approach is restricted due to the shortage of
donor tissues and ethical concerns [3]. Thus, the possibility
of generating DA neurons from hESCs offers an alternative
source of cells for regenerating DA neurons in the midbrain
of PD patients [4].
Derivation of specific cell types from hESCs becomes
more attractive due to the recent approval of clinical trials
using hESC derivatives to treat several neurodegenerative
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diseases, such as spinal cord injury and age-related macular
degeneration. It has been shown that neural progenitor cells
can be differentiated from hESCs and that they exhibit broad
cellular spectrum with respect to developmental and lineage
specification [5, 6]. Differentiation of hESCs in an adherent
culture reveals striking similarity between in vitro differenti-
ation and in vivo embryonic formation of neuroectoderm [7].
BMP antagonismhas been considered as the central initiating
event in neural induction and neuroepithelial specification
that occurs as a default pathway [8]. The antineurogenic
effect of BMPs is thought to be, at least, partly mediated
via induction of gene expression for ID1 and ID3, helix-
loop-helix transcription factors important for proper neural
development [9, 10]. ID proteins act as dominant-negative
regulators that interfere with the transcriptional activities
of proneural proteins in neural progenitor cells [11]. Neu-
ral progenitor cells have been successfully generated from
hESCs by applying Noggin, one of the BMP antagonists;
nonetheless, the high cost of recombinant Noggin hampers
the applicability of this protocol [5]. Alternatively, small
molecules blocking both BMP and Activin/nodal pathways
have also been used in inducing neural differentiation from
human pluripotent stem cells. However, this dual inhibition
of SMAD signaling is often accompanied with a massive
cell death, which might limit the application when a large
number of cells are needed [6, 12]. It is noted that neural
differentiation is a dynamic process. Various stages of neural
derivatives are generated, which show distinct properties [7].
During the differentiation of hES cells, neural progenitors
transit from a predominantly neuronal state into one with
increased gliogenic potential. This phenomenon resembles
what is found in embryonic neurogenesis [13].
Following neural lineage specification, it is critical to
establish the positional information that could induce pheno-
types of a particular type of neurons. Gradients of signaling
molecules can regionally specify a population of neural
progenitor cells [14]. This achievement will accelerate the
progress of potential uses of hESCs in cell replacement for
neurodegenerative diseases, including Parkinson’s disease.
DA neurons have been derived from human pluripotent stem
cells by the forced expression of key developmental genes for
neuronal fate, such as LMX1a and ATOH1 [15, 16]. Although
this transgene strategy offers a high-yield production of DA
neurons, the contamination of exogenous DNA hinders the
applicability of the resulting neurons in PD patients. It is
known that sonic hedgehog (SHH) and fibroblast growth
factor 8 (FGF8) regulate the initial stages of DA neuronal
development to specify DA progenitors in the medial ventral
area of the midbrain [17]. These extrinsic factors control a
number of key transcription factors such as NGN2, MASH1,
FOXA2, LMX1a, LMX1b, NURR1, and PITX3 that are crucial
for DA neurogenesis [18–20]. The supplementation of SHH
and FGF8 should guide neural progenitor cells to becomeDA
neurons in vitro.
In this study, we optimized the differentiation system to
induce hESCs into neural lineage by a single small molecule
Dorsomorphin. The resulting neural progenitor cells were
then directed to DA neurons by using the two key patterning
molecules, FGF8 and SHH.
2. Results
2.1. Dorsomorphin Is a Strong Neural Lineage Inducer. hESCs
can be efficiently induced into neural lineage by a potent
BMP inhibitor, such as Noggin [5]. However, continuous
supplementation of recombinant Noggin is costly since the
initiation of neural lineage from hESCs takes several days.
In this study, we used Dorsomorphin, a small chemical
compound, to specifically inhibit BMP signaling pathway
[21]. The effect of different concentrations (5 𝜇M, 10 𝜇M,
and 20𝜇M) of Dorsomorphin on the expression of BMP
effector genes, including ID1 and ID3, as well as BMP ligands,
BMP2 and BMP4, was first tested. After 5 days, expression
of these genes was downregulated (Figure 1(a)) even with the
5 𝜇M Dorsomorphin, and, therefore, this concentration was
employed in subsequent experiments. hESCs transformed
from epithelial structures (D0; Figure 1(b)) and appeared as
distinct morphology after the differentiation process began
(day 5; Figure 1(b)). A trivial number of death cells were
observed. Thereafter, cells were spontaneously patterned to
form neural rosette structures, in which the cell morphology
was similar to that of neuroepithelium (day 15; Figure 1(b)).
A similar morphological change was also observed in human
induced pluripotent stem cells (data not shown). During this
initiation stage, BMP inhibitor, Dorsomorphin, is required
to block extraembryonic endoderm differentiation. After the
formation of neural rosette structures, Dorsomorphin was
replaced by 10 ng/mL bFGF in the neural differentiation
medium and the cells exhibited bipolar structure, a typical
morphology of neural progenitor cells, and we named these
cells as hES-NP cells (day 25; Figure 1(b)). Gene expression
was examined along the differentiation process of hES-NP
cells by RT-PCR. Pluripotent genes, OCT4 and NANOG,
were downregulated, coinciding with the upregulation of
neural lineage markers, MASH1 and PAX6 (Figure 1(c)).
Expression of other lineage markers, such as GATA6 and
Brachyury, was not detected, indicating that no other cell
types were generated under the current differentiation system
(Figure 1(c)). Immunocytochemistry results revealed homo-
geneous expression of neural progenitor markers, including
SOX1,MASH1, andNESTIN (Figure 1(d)). Interestingly, hES-
NP cells expressed PSA-NCAM, a marker of intermediate
neural progenitor cells [22] (Figure 1(d)). This set of markers
is considered as diagnostic molecules for embryonic neural
stem cells [23].
2.2. hES-NP Cells Are Multipotent. One of the key charac-
teristics of neural progenitor cells is multipotency, that is,
the ability to give rise to several types of neuronal cells. To
examine the differentiation potency of hES-NP cells, the cells
were subjected to further differentiation. Neurospheres of
hES-NP cellswere formed in low attachment dishwithN2B27
medium, supplemented with 1% fetal calf serum (FCS).
After 2 weeks, hES-NP cells were plated onto coverslips
for immunocytochemistry. Differentiated hES-NP cells were
positive for neuronal marker 𝛽-tubulin III and astrocyte
marker GFAP, while markers for oligodendrocytes were
absent (Figure 2). To induce oligodendrocytes from hES-NP
cells, cells were cultured in N2 medium, supplemented with
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Figure 1: Differentiation of neural progenitor cells fromhESCs by using smallmolecules. (a)Dorsomorphin, a smallmolecule inhibiting BMP
signaling, was tested at various concentrations. (b) Morphology of hESCs transformed during the differentiation. Neural rosette structures
appeared after 15 days of the differentiation prior to the generation of bipolar neural progenitor cells. (c) Gene expression analysis at different
days of the differentiation. Pluripotency genes were downregulated, while neural progenitor genes were increased along the differentiation.
GATA6 and Brachyury were not detected during neural differentiation. (d) Neural progenitor cells homogeneously expressed SOX1, PSA-
NCAM, and NESTIN.
PDGF, Forskolin, platelet-derived growth factor (PDGF),
triiodothyronine (T3), and ascorbic acid, as described in
Materials andMethods. Oligodendrocytes were rarely gener-
ated, consistent with previous studies [24, 25]. In addition to
simple neuronal differentiation, hES-NP cells could give rise
to specific neuronal subtypes, for example, GABAergic and
DA neurons even at low frequency (Figure 2). These results
confirmed the multipotency of hES-NP cells.
2.3. hES-NP Cells Have Low CBF1 Responsiveness. Notch
signaling is well known to regulate neural lineage initiation,
neural stem cell maintenance, and cell fate determination
[26]. The activation of canonical Notch signalling pathway
through C-promoter binding factor 1 (CBF1) plays a critical
role in the signaling transduction [27]. Differential response
to CBF1 is an important feature to distinguish the state of
neural progenitor cells from neural stem cells, which is inde-
pendent of activation of Notch receptors [28]. During neural
differentiation process of hES cells, various stages of neural
derivatives have emerged, including early neural progenitors
and GFAP-positive neural stem cells [7]. To elucidate that
hES-NP cells resemble embryonic neural progenitor cells,
CBF1 responsiveness was evaluated, and hES-neural stem
cells, as described in Materials and Methods, were used as
a comparison. CBF1 responsiveness was demonstrated by
transient transfection of CBF1-responsive reporter plasmids,
in which the reporter genes, GFP and luciferase, are driven by
promoter containing 4 CBF1-responsive elements. The result
showed that most of hES-neural stem cells (∼70%) expressed
CBF1-GFP while only small population (∼20%) of the hES-
NP cells did (Figures 3(a)–3(c)). Furthermore, luciferase
assay displayed a similar pattern that hES-neural stem cells
exhibited 3 times higher CBF1-luciferase activity than that of
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Figure 2: Differentiation potential of neural progenitor cells derived
from human embryonic stem cells. In order to induce terminal
differentiation, neural progenitor cells were let to formneurospheres
for 7 days. The cells were then replated, immunostained, and found
to give rise to several cell types, such as oligodendrocytes (O4),
GABAergic neurons (GABA), and dopaminergic neurons (TH).
TUJ1-positive neurons (red) and GFAP-positive glial cells were
codetected in differentiating culture.
hES-NP cells (Figure 3(d)). These results demonstrated that
hES-NP cells had minimal response to CBF1, whereas hES-
neural stem responds to it well. This evidence suggested that
hES-NP cells resembled embryonic neural progenitor cells,
found early during neurogenesis.
2.4. hES-NP Cells Are Mitotically Responsive to bFGF. Dur-
ing embryonic neurodevelopment, proliferation of neural
progenitor cells is regulated by a variety of soluble factors,
including bFGF and EGF. Neural progenitor cells require
bFGF and EGF at different stages of brain development. Sur-
vival and proliferation of embryonic progenitor cells appear
to be regulated by bFGF and predisposed toward neuronal
differentiation [29]. On the other hand, later in the develop-
ment, EGF-responsive progenitor cells are the predominant
species and are likely to become more glial lineages [30].
It is interesting to examine the mitogenic response of hES-
NPCs, which might reflect their developmental state of an
in vivo counterpart. Mitogenic response of hES-NP cells was
examined by BrdU cell division assay and MTT cell prolifer-
ation assay (Figure 4). It appeared that hES-NPC population
responded well to bFGF supplementation (Figure 4(a)). hES-
NP cells significantly increased the percentage of dividing
cells, from 13.2%± 0.8% to 61.7%± 6.3%, upon the addition of
10 ng/mL bFGF (Figure 4(b)). The mitogenic effect of bFGF
on hES-NP cells was confirmed by MTT cell proliferation
assay. Addition of 10 ng/mL bFGF significantly promoted the
proliferation of hES-NP cells after 5 days of the experiment
(Figure 4(c)).
2.5. Dopaminergic Neurons Can Be Derived from Neural
Progenitor Cells. In addition to glial-neuron differentiation,
hES-NP cells were examined for their differentiation into
dopaminergic (DA) neurons by supplementing two devel-
opmental cues for DA neurogenesis, SHH and FGF8 [31–
33]. Ventral midbrain/hindbrain fates of hES-NP cells were
induced by exposure to FGF8 and SHH followed by treat-
ment with neurotrophic factors, including BDNF, GDNF,
ascorbic acid, and laminin (Figure 5(a)). When subjecting
hES-NP cells to such differentiation regime, they showed
mature neuronal structure and were positive for MAP2/TH
immunostaining, hallmark characteristics of DA neurons
(Figure 5(b)). A significant number of hES-NP cells became
MAP2/TH-double positiveDAneurons (10.6%± 1.2%), while
only 3.8% ± 1.3% of MAP2/TH-double positive cells were
found in the control differentiating medium (without any
growth factors) (Figure 5(c)). However, it is necessary to
confirm that DA neurons generated in these experiments
were midbrain-origin which are promisingly required for the
treatment of Parkinson’s disease.We examined the expression
of molecular markers of midbrain in DA neurons derived
from hES-NP cells at various conditions: (1) prior to the
induction toward DA neurons (+GF), (2) without the sup-
plementation of growth factors (−GF), (3) in the presence
of 1% fetal calf serum (+FCS), and (4) DA neuron-inducing
conditions (DA) as stated above. The pan-neuronal genes,
MASH1 and PAX6, did not show variable expression among
the different culture conditions; however, NURR1, PITX1,
and EN1 were clearly upregulated in the DA conditions
(Figure 5(d)). This verified that hES-NP cells could serve as
an expandable source for DA neurons. The adjustment of
regional identities via morphogens mimics environmental
cues found in the embryonic brains.
3. Discussion
Neurogenesis in mammals is a complex process involving
many different cell types that differentiate asynchronously.
Our understanding about it is far from complete. In addition
to the complicated process, the relatively small number of
neuronal cells that can be readily obtained from embryonic
brain makes the study of the neural development extremely
difficult. hESCs are derived from early embryos and have the
potential to generate all the cell types in the nervous system;
therefore, they should be a suitable in vitromodel for studying
neural development [34, 35]. In early development, neural
progenitor cells transit from NESTIN-positive single layer
neuroepithelial cells to S100𝛽-positive radial glial cells and
eventually give rise to GFAP-positive adult neural stem cells
[36]. Several studies have reported the generation of mouse
ESC-derived progenitor cells with radial glial properties that
can be propagated in the presence of bFGF [37, 38]. hES-
NP cells can also be propagated in the presence of bFGF,
liberated from any requirement for a specific cellular niche.
The cells exhibited multiple prominent characteristics: (1)
stability in a long-term culture (>100 days), (2) ability to
produce neurons and glia, and (3) expression of neural
progenitor markers, indicating the appropriateness of our
culture system to maintain neural progenitor identity. This
study highlights that hES-NP cells are similar to embryonic
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Figure 3: Low CBF1 response of neural progenitor cells. ((a)–(c)) CBF1 response of cells was measured by transient transfection of GFP-
reporter plasmid. ((a) and (b)) Phase contrast and fluorescence images of neural progenitor cells and neural progenitor/stem cells, respectively.
Scale bar represented 50𝜇M for all images. (c) Histogram showed percentage of CBF1-responsive cells. (d) Histogram presented luciferase
activity controlled by CBF1. Three independent experiments were performed with a standard deviation bar and ∗ represented 𝑝 < 0.005
(Student’s t-test).
neural progenitors in several ways, including the detection
of PSA-NCAM expression and mitogenic responsiveness to
bFGF [23, 29]. In addition, the differential use of Notch
signaling, in particular with respect to CBF1 activation, is
a mechanism used to distinguish the state of cells, whether
they are neural progenitors or neural stem cells [28]. Here
we showed that CBF1 responsiveness of hES-NP cells was
considerably low, comparing to hES-neural stem cells. This
data is in accordance with the growth factor responsiveness,
showing that hES-NP cells mitotically responded to bFGF
(Figure 4). These results altogether implied that hES-NP
cells are similar, at certain degree, to embryonic neural
progenitor cells. Moreover, this result indicates that the
activation or blockade of canonical Notch-CBF1 cascade may
direct expression of different target genes, which determine
the neural/glial potency of neural progenitor cells [39]. The
capacity of hES-NP cells to respond to patterning cues, which
are here FGF8 and SHH, emphasizes the potential use of these
cells for regenerative medicine.
Several available protocols showed that targeting SMAD
signaling can induce hESCs towardneural lineage by suppres-
sion of alternative embryonic germ layers [6, 12, 40, 41]. How-
ever, the simultaneous blockade of BMP- and Activin/TGF-
𝛽-mediated SMAD signaling pathways results in gross cell
death at the initial phase of the differentiation.The inhibition
of BMP signaling alone by Noggin showed efficient neural
differentiation; however, this routine supplementation of
recombinant protein is costly [5]. In this study, we modified
the protocol for neural differentiation from hESCs by using a
single small molecule Dorsomorphin that can inhibit BMP
signaling and found that this compound is sufficient to
convert hESCs into neural progenitor cells. As compared to
Noggin, Dorsomorphin has awider action on BMP signalling
because it blocks BMP signalling at receptor level, rather
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Figure 4: Proliferation capacity of neural progenitor cells derived from human embryonic stem cells. bFGF can promote proliferation of
neural progenitor cells. (a) BrdU assay showed the increased proliferation of neural progenitor cells upon the addition of bFGF. (b) The
number of BrdU-positive cells was significantly higher than in the control cells. (c) MTT assay confirmed the effect of bFGF on neural
progenitor cell proliferation. Data are presented as mean ± s.d. (𝑛 = 3). ∗ represents 𝑝 < 0.05 by Student’s 𝑡-test.
than binding and inhibiting a distinct set of BMP proteins as
Noggin does [21, 42]. Besides ALK receptors, Dorsomorphin
also inhibits the activity of several other kinase enzymes
and thereby modulates cell physiology through multiple sig-
nalling pathways thatmight facilitate neural differentiation of
hESCs [21]. In contrast to other studies, we blocked only BMP
signalling, but not Activin/TGF-𝛽 pathway with SB431542. It
has been reported that Activin/TGF-𝛽 pathway is important
for neuronal cell development and survival [43, 44]. More-
over, instead of N2 supplement, we usedN2B27 as an additive
to the basal medium. B27 supplement is comprised of an
enriched combination of insulin and multiple antioxidant
substances that may promote the proliferation and survival
of neural progenitor cells [45, 46].
Since hES-NP cells are uncommitted and proliferative,
they could serve as a scalable source for the production
of various types of neurons and glial cells for toxicant
and pharmaceutical screening and, ultimately, for cell-based
replacement therapy. It will be important to determine hES-
NPC differentiation capacity to generate different neuronal
subtypes in vitro and in vivo and whether or how the
cells can contribute functional reconstruction in diseased
animals. Here we presented that a substantial number of
DA neurons could be obtained from hES-NP cells following
the exposure of FGF8 and SHH. Differentiation efficiency of
dopaminergic neurons could also be enhanced by using a
recombinantmidbrain factor, for instance, LMX1A [47]. Nev-
ertheless, further development of culture systems, combining
with tissue engineering technology, will offer an improved
microenvironment and increase differentiation efficiency of
hES-NP cells toward DA neurons [48]. The clinical grade
differentiation system to produce DA neurons should be
developed in order to translate these cells into clinical uses
[49]. Besides DA neurons, other neuronal subtypes should
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Figure 5: Direct dopaminergic neuron differentiation from neural progenitor cells. (a) Schematic of differentiation conditions for DA
neurons from neural progenitors. (b) Phase contrast pictures showing morphological changes of cells during the differentiation. Cells were
immunostained againstMAP2 andTH, indicating dopaminergic neuron phenotypes. (c)Thenumber of TH-positive neurons inDA-inducing
condition (DA) was significantly greater than that without growth factor condition (−GF). Data are presented as mean ± s.d. (𝑛 = 3). ∗
represents 𝑝 < 0.05 by Student’s 𝑡-test. (d) Gene expression result suggested that differentiated neural progenitor cells in DA condition
expressed midbrain dopaminergic neuron markers, including NURR1, PITX3, and EN1.
be able to obtain from hES-NP cells when appropriate con-
ditions are applied such as cholinergic neurons, GABAergic
neurons, and glutaminergic neurons. The development of
neuronal subtype specification protocols will expand the
application of hES-NP cells to other neurological diseases.
Altogether, this study provided a system for generating neural
progenitor cells from hESCs by using a single BMP inhibitor
Dorsomorphin. Moreover, the resulting hES-NP cells could
serve as an expandable source for DA neurons production,
which could be applied for various purposes.
4. Materials and Methods
4.1. Culture of Human Pluripotent Stem Cell. H7 and H9
hESCs (WiCell) and Hell11.4 iPSCs were cultured in Geltrex-
coated plates with Stem Pro complete medium (Invitro-
gen) and routinely propagated with combination of 0.02%
PBS/EDTA treatment and mechanic dissociation.
4.2. Differentiation and Culturing Conditions of Neural Pro-
genitor Cells Derived from hESCs. Confluent H9 hESCs were
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split with 0.02% EDTA/PBS (Sigma) in 1 : 5 ratios into culture
dishes coated with Geltrex (Invitrogen) and cultured in
N2B27medium (all supplements fromGibco), supplemented
with 5 𝜇M Dorsomorphin (Sigma). At this stage, cells were
defined as passage 1 (P1) and the cell was called hES-NP
cells. In the neural differentiation, the cells were consistently
cultured in the Geltrex-coated culture plates. Cells of P1
and P2 were split by 0.02% EDTA/PBS (Sigma) into small
clumps, similar to hESC culture, and continuously cultured
in N2B27 medium plus Dorsomorphin. From P3, cells were
dissociated into single cells by TrypLE express (Gibco), and
Dorsomorphin could be withdrawn from N2B27 medium
with the addition of 10 ng/mL bFGF. The cells were able to
survive in long-term culture. hES-NP cells gradually change
their morphology and gene expression profile, when cultured
over passage 30, and we termed these cells as hES-neural
stem cells. To induce postmitotic cell types, hES-NP cells were
cultured in the basal medium without growth factors for 2
weeks.
4.3. Differentiation of Oligodendrocytes from hES-NP Cells.
hES-NP cells were plated on PLL/laminin-coated dishes and
the neural stem cell expansionmedium (N2B27)was replaced
by DMEM/F12 supplemented with N2 (N2 medium). Cells
were proliferated in the presence of 10 ng/mL PDGF and
10mM Forskolin for 7 days to support a glial precursor
stage. Further differentiation was induced by a 7-day-growth
culture in the presence of 10 ng/mL PDGF, 30 ng/mL 3, 3, 5-
triiodothyronine (T3), and 200𝜇M ascorbic acid (AA).
4.4. Differentiation of DA Neurons from hES-NP Cells. Neu-
ral progenitor cells were seeded in PLL/Lam-coated cul-
ture dishes and induced with sonic hedgehog (400 ng/mL),
FGF8 (100 ng/mL), and ascorbic acid (160 𝜇M) for 2 weeks
and then followed by brain-derived neurotrophic factor
(BDNF) (20 ng/mL), glial cell line-derived neurotrophic fac-
tor (GDNF) (20 ng/mL), ascorbic acid (160 𝜇M), and laminin
(0.5 𝜇g/mL) for another week. RT-PCR and immunocyto-
chemistry were performed to characterize phenotypes of the
cells.
4.5. Reverse Transcription and Polymerase Chain Reaction
(RT-PCR). Total RNA was extracted using RNA Spin II
(Macherey-Nagel) by following the manufacturer’s instruc-
tions. First-strand cDNA was synthesized from 2 𝜇g total
RNA by SuperScript III reverse transcriptase (Invitrogen)
with oligo dT primer (Invitrogen) in 20𝜇L volume. cDNA
solution was diluted 1/10 in dH
2
O and 2 𝜇L was used for each
PCR reaction. The list of target gene primers was supplied.
4.6. Immunocytochemistry. Cells were fixed at room temper-
ature with 4% paraformaldehyde for 10 minutes. Nonspecific
proteins were blocked by incubation in phosphate buffered
saline (PBS) containing 10% fetal bovine serum (Sigma) and
0.1% Triton X-100 for one hour at room temperature. The
cells were then treated with primary antibodies overnight at
4∘C. After washing with PBS, the cells were incubated with
fluorescence-conjugated secondary antibody for 45 minutes
and finally mounted to cover slip with Vectashield mounting
mediumwithDAPI (Vectorlabs).The following primary anti-
bodieswere used in this study:monoclonal antibodies against
TH, NESTIN (1 : 200, all from Chemicon), and 𝛽-tubulin III
(Sigma, 1 : 1000); rabbit polyclonal againstMusashi-1 (1 : 200),
MAP2 (1 : 1000, all from Chemicon), SOX1 (1 : 100), SOX2
(1 : 50; all from Abcam), and glial fibrillary acidic protein
(GFAP; 1 : 500; Dako Cytomation). Secondary antibodies
used were goat anti-mouse immunoglobulin Alex Fluor 568
and goat anti-rabbit Alex Fluor 488 (all at 1 : 400; Molecular
Probes).
4.7. BrdU Cell Division Assay. Cells cultured on PLL/laminin
precoated cover slip in 24-well plates were incubated with
BrdU at a final concentration of 10 𝜇M at 37∘C for 2 hours.
After washing with PBS, cells were fixed for 10 minutes in
freshly prepared 4% paraformaldehyde. After washing again,
cells were incubated with 2M HCl at 37∘C for 1 hour to
denature the DNA, followed by incubation for 1 hour in
blocking buffer containing 10% goat serum, 0.5% Triton X-
100. The cells were then treated with monoclonal antibody
against BrdU for 1 hour and secondary antibody for 30
minutes in darkwith PBSwashing in between.The slideswere
mounted and left to dry before visualization.
4.8. MTT Cell Proliferation Assay. MTT stock solution was
prepared at a concentration of 5mg/mL in PBS and stored
at 4∘C. 25 𝜇L of MTT solution was added to each well and
the cells were incubated for 2 hours to allow the reaction to
occur. Then, 100 𝜇L MTT lysis buffer (10% SDS) was added
to each well, and the plates incubated overnight to ensure
that the hypermetabolic cellular states will not interfere
with the final reading. MTT conversion has determined the
absorbance/optical density (OD) at 562 nm. Lysis controls
were used to give background control reading.
4.9. Luciferase Activity Assay. Dual-luciferase reporter
(DLR) assay system was used to determine luciferase activity
following the manufacturer’s protocol. Briefly, to prepare
stock solution, luciferase assay reagent II (LAR II) was
prepared by resuspending the lyophilized substrate in 10mL
of the supplied buffer II. LAR II solution was kept at −80∘C
until used. Stop&Glo reagent was diluted just prior to the
assay for a desired volume with the provided buffer. Cells
were transfected for 48 hours with the firefly reporter and
Renilla luciferase vectors and then lysed by 500𝜇L passive
lysis buffer (PLB) before being transferred to a 1.5 mL tube.
100 𝜇L of LAR II was predispensed into the appropriate
number of luminometer plates to complete the desired
number of DLR assays. 20𝜇L of cell lysate was carefully
transferred to the luminometer plate containing LAR II,
mixed by pipetting and initiated reading by the luminometer.
Next, 100 𝜇L of prepared Stop&Glo reagent was added to the
previous mixture, mixed by pipetting and initiated reading.
Calculation of luciferase activity was determined by relatively
comparing the activity of firefly and Renilla luciferase.
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